

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-18 have been canceled.

Claim 19. (Currently amended) An aqueous pharmaceutical formulation in the form of a nasal spray comprising an effective amount of an ~~an~~ ~~ketorolac-based~~ analgesic comprising ketorolac, an optical isomer thereof, or a salt thereof admixed with a phospholipid or a bioadhesive polymer, said spray when administered to a human subject intranasally having a therapeutic blood level comparable to that of the same formulation when injected will generate plasma levels of ketorolac in the subject within the range of 0.3-5 mg/liter of plasma.

Claim 20. (Currently amended) The pharmaceutical nasal spray of claim 19 wherein the ~~ketorolac-based~~ analgesic is ketorolac tromethamine.

Claim 21. (Previously presented) The pharmaceutical nasal spray of claim 19 wherein the analgesic is present in the composition in an amount of between 5 to 20% by weight based on total weight of the composition.

Claim 22. (Previously presented) The pharmaceutical nasal spray of claim 21 wherein the analgesic is present in the composition in an amount of 15% by weight based on total weight of the composition.

Claim 23. (Previously presented) The pharmaceutical nasal spray of claim 19 wherein the bioadhesive polymer is selected from the group consisting of polyacrylics, cellulose, and gums.

Claim 24. (Previously presented) The pharmaceutical nasal spray of claim 19, said spray being free of absorption enhancers.

Claim 25. (Canceled)

Claim 26. (New) A pharmaceutical formulation in the form of a nasal spray comprising an effective amount of an analgesic comprising ketorolac, an optical isomer thereof, or a salt thereof admixed with a bioadhesive polymer, said spray when administered to a human subject intranasally forms a gel and will generate plasma levels of ketorolac in the subject within the range of 0.3-5 mg/liter of plasma.

Claim 27. (New) The pharmaceutical nasal spray of claim 26 wherein the analgesic is ketorolac tromethamine.

Claim 28. (New) The pharmaceutical nasal spray of claim 26 wherein the analgesic is present in the composition in an amount of between 5 to 20% by weight based on total weight of the composition.

Claim 29. (New) The pharmaceutical nasal spray of claim 28 wherein the analgesic is present in the composition in an amount of 15% by weight based on total weight of the composition.

Claim 30. (New) The pharmaceutical nasal spray of claim 26 wherein the bioadhesive polymer is selected from the group consisting of polyacrylics, cellulose, and gums.

Claim 31. (New) The pharmaceutical nasal spray of claim 26, said spray being free of absorption enhancers.